The study found that those who had been taking semaglutide or lixisenatide for at least six months had twice the risk of developing macular degeneration, compared with similar patients who were not taking the drugs. Patients who had been taking GLP-1 RAs for more than 30 months had more than three times the risk.
2 Likes
This is an alarming possibility. I wonder if non- diabetics using GLP-1 RA drugs are at increased risk.
2 Likes
I love statistics. Given a careful choice of data I can prove anything I want to prove. Well, I don’t really want to prove anything so it’s kinda easy.
Now, of course, if those patients would not have died but for the GLP-1s then the explanation is obvious. My statement is also true.
Conclusions and Relevance In this cohort study, the use of GLP-1 RAs among patients with diabetes was associated with a 2-fold higher risk of incident nAMD development than among similar patients with diabetes who did not receive a GLP-1 RA. Further research is needed to elucidate the exact pathophysiological mechanisms involved and to understand the trade-offs between the benefits and risks of GLP-1 RAs.
“pathophysiological”, nothing like a long word to scare everyone off.
It’s primary research dudes; it means nothing, sorry nada. It’s the Guardian full of shyte. Wait until the other dudes replicate it then get scared. Funny, my eyesight is getting worse yet I’ve never toked a GLP-1 in my life.
BTW for the 100% of people who do not understand what I just said this (the link to the actual paper) is a completely valid piece of research but the other, the Guardian article, is a piece of shyte.
1 Like